Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 4/20 | 0.39 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.38 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162669 | 0.91 | HTR2C (0.57) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| SCHEMBL163850 | 0.91 | HTR2C (0.57) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| Bromide SCHEMBL161200 | 0.90 | HTR2C (0.56) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| Iodide SCHEMBL162026 | 0.90 | HTR2C (0.56) | HTR2CHTR2AHTR2BTAAR1PRCP | |
| Nitric Acid SCHEMBL163517 | 0.86 | HTR2C (0.47) | HTR2CHTR2AHTR2BTAAR1TSHR | |
| SCHEMBL158569 | 0.86 | HTR2C (0.50) | HTR2CHTR2AHTR2BTAAR1TSHR | |
| Glycolic Acid SCHEMBL162065 | 0.86 | TAAR1 (0.47) | HTR2CHTR2AHTR2BTAAR1TSHR | |
| Malonic Acid SCHEMBL160930 | 0.86 | TAAR1 (0.47) | HTR2CHTR2AHTR2BTAAR1TSHR | |
| Succinic Acid SCHEMBL161276 | 0.86 | TAAR1 (0.47) | HTR2CHTR2AHTR2BTAAR1TSHR | |
| Fumaric Acid SCHEMBL159722 | 0.85 | TAAR1 (0.46) | HTR2CHTR2AHTR2BTAAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |